Colorectal cancer (CRC) is the third-leading cause of cancer mortality in the United States and other industrialized countries. A hypoxic microenvironment is a hallmark for solid tumors. The hypoxia-induced signal transduction is transcriptionally mediated by hypoxia-inducible factor (HIF). Three major HIF isoforms, HIF-1␣, HIF-2␣, and HIF-3␣, are present in the intestine. Our previous work demonstrates that HIF-2␣ is essential for CRC growth and progression. However, the mechanisms mediating cell proliferation after hypoxia or HIF-2␣ activation in CRC are unclear. Data mining of RNA-Seq experiments with mouse models of intestinal HIF-2␣ or Yes-associated protein 1 (YAP1) overexpression indicates a significant overlap of genes in these conditions. YAP1 is a transcriptional co-activator in the Hippo signaling pathway, and YAP1-induced transcriptional responses are essential in cancer cell proliferation. Here, we report that HIF-2␣ robustly increases YAP1 expression and activity in CRC-derived cell lines and in mouse models. The potentiation of YAP1 activity by HIF-2␣ was not via canonical signaling mechanisms such as Src (non-receptor tyrosine kinase), PI3K, ERK, or MAPK pathways. Moreover, we detected no direct interaction of HIF-2␣ with YAP1. Of note, YAP1 activation was critical for cancer cell growth under hypoxia. Our findings indicate that HIF-2␣ increases cancer cell growth by up-regulating YAP1 activity, suggesting that this pathway might be targeted in potential anti-cancer approaches for treating CRC patients.
In response to hypoxia, tumor cells activate genes that are critical in angiogenesis, cell survival, cell proliferation, and glucose metabolism (3) . Hypoxia-induced responses are transcriptionally mediated by hypoxia-inducible factor-1␣ (HIF-1␣), HIF-2␣, and HIF-3␣, which are members of the Per-ARNT-Sim family of basic helix-loop-helix transcription factors that bind hypoxia response elements at target gene loci under hypoxic conditions (4, 5) . Among the HIFs, HIF-2␣ is essential in CRC growth and progression. Our recent work has demonstrated an essential role of HIF-2␣-induced epithelial-elicited inflammation and regulation of intratumoral iron homeostasis as important mechanisms leading to increase in colon cancer (6, 7) . In cancer-derived cell lines and in renal carcinomas, HIF-2␣ induces proliferation via an increase in c-Myc activity (8, 9) . However, in CRC, mechanisms of hypoxic and HIF-2␣ potentiation of cancer cell growth are unclear.
Hippo signaling is a central pathway that regulates intestinal growth. Yes-associated protein 1 (YAP1) is a downstream effector in the Hippo signaling pathway, which functions as an essential regulator of proliferation, organ size, and cell differentiation (10, 11) . In response to a decrease in Hippo signaling, YAP1 translocates into the nucleus and acts as transcriptional co-activator to the transcriptional enhancer factors (TEA) domain (TEAD) family of transcription factors (TEAD1-4) (12, 13) . YAP1 is dispensable for normal intestinal homeostasis but is absolutely required for intestinal regeneration after tissue injury (14) . Recent work has demonstrated that the growthpromoting role of YAP1 is critical for the proliferative response observed during intestinal inflammation as well as in sporadic CRC (15, 16) . Interestingly, intestine-specific YAP1-overexpressing mice restrict ␤-catenin activation, and under radiation-induced injury, deletion of intestinal YAP1 leads to hyperproliferation (17) . This discrepancy is perhaps due to the complex interaction of YAP1 with APC/␤-catenin signaling in intestinal epithelial cells (18 -22) . However, several studies have demonstrated an important role of YAP1 as an essential transcription factor in mouse models of colon cancer (14, 15, 23) . The role of HIF-2␣ in YAP1 signaling pathway has not been studied.
In the current study we found a novel role of hypoxia via HIF-2␣ in activating YAP1. Moreover, the increase in YAP1 by HIF-2␣ is essential for cell growth during hypoxic stress in colon-derived cell lines. The study provides a novel HIF-2␣/ cro ARTICLE YAP1-signaling pathway that maybe targeted in cancer treatment.
Results

HIF-2␣ increases YAP1 transcriptional activity
To investigate the mechanisms of HIF-2␣-induced cell proliferation, RNA-sequencing data were analyzed in a mouse model of HIF-2␣ overexpression specifically in intestinal epithelial cells (HIF2␣ LSL/LSL;VillinCre ) (24) . Interestingly, the data showed an increased expression of several well-characterized YAP1 target genes: Cyr61, Ctgf, Tgfbr2, and Tead1. To assess the global regulation of YAP1 target genes by HIF-2␣, data were compared from the HIF2␣ LSL/LSL;VillinCre mice and global gene expression profiles from mice, which have a constitutive activated YAP1 in intestinal epithelial cells (17) . 484 genes (279 down-regulated and 205 up-regulated genes) were commonly regulated in YAP1-and HIF-2␣-overexpressing mice (Fig. 1, A  and B ). This suggests a potential cross-talk between HIF-2␣ and YAP1 signaling. These commonly regulated genes by HIF-2␣ and YAP1 are involved in not only Hippo signaling pathway but also several other pathways including MAPK, PI3K-AKT, and TGF-␤ signaling pathways ( Fig. 1, A and B) . To confirm these changes Western blot analyses and quantitative PCR (qPCR) were performed in HIF2␣ LSL/LSL;VillinCre mice for YAP1 signaling and target genes. In the HIF2␣ LSL/LSL;VillinCre mice a significant increase in total-YAP1 protein levels and YAP1 target genes, Cyr61, Ctgf, and Tgfbr2 were observed, whereas HIF-1␣ overexpression decreased YAP1 target genes Tgfbr2 and Tead1 ( Fig. 2A ). This indicates that HIF-2␣, but not HIF-1␣, increases YAP1 activity. To demonstrate this was a cell autonomous function of HIF-2␣, an oxygen-stable HIF-2␣ was stably overexpressed in HCT116 colon cancer cell line ( Fig. 2B ). Consistent with in vivo data, the overexpression of HIF-2␣ in HCT116 significantly increased YAP1 target genes Cyr61 and Ctgf expression ( Fig. 2C ). Western blotting and immunofluorescent staining showed that HIF-2␣ overexpression significantly increased both total YAP1 (T-YAP1) and phospho-YAP1 (p-YAP1) protein levels and nuclear YAP1 localization without altering the p-YAP/T-YAP1 ratio (Fig. 1, E and F) . These data confirm that HIF-2␣ increases the expression of YAP1 target genes.
HIF-2␣ potentiates YAP1 activity
The Cyr61 promoter luciferase (25) and a synthetic promoter consisting of 8ϫ tandem TEAD-binding sites (GTIIC) upstream of a luciferase reporter (26) were assessed for YAP1 activity. Consistent with a previous study, YAP1 significantly increased Cyr61 and GTIIC promoter activities in all of the cell lines assessed (Fig. 3, A and B) . Interestingly, HIF-2␣ increased basal Cry61 activity in SW480 and HEK293 cell lines ( Fig. 3A ) and potentiated the YAP1 transcriptional activity on the Cyr61 
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and GTIIC promoter in the cell lines assessed (Fig. 3, A and B) . These data indicated that HIF-2␣ potentiates YAP1 activity.
Increased YAP1 activity in sporadic tumors is HIF-2␣ independent
YAP1 is important for cell proliferation, adenoma formation, and cancer development (27) (28) (29) . In addition, previous reports suggested that YAP is part of ␤-catenin signal cascade and is directly activated after the loss of APC (18, 20 -22) . To further understand if HIF-2␣ is essential for YAP1 activation after APC disruption, a novel mouse model was generated using a tamoxifen-inducible colon-specific Cre (CDX2ERT2 cre ) (30) . The CDX2ERT2 cre mice were crossed to the Apc floxed mice (CDXERT2 Cre /Apc F/F ) or crossed to the Apc and Hif2␣ floxed mice (CDXERT2 Cre Apc F/F /Hif2␣ F/F ). 7-Days after tamoxifen treatment, Hif2␣ and HIF-2␣ target gene Scl11a2 were significantly decreased in Hif2␣ floxed mice (CDXERT2 Cre Apc F/F / Hif2␣ F/F ) compared with CDXERT2 Cre /Apc F/F group (Fig. 4A ). Consistent with previous work (31), Cyr61 and CTGF genes were induced in both CDXERT2 Cre Apc F/F and CDXERT2 Cre Apc F/F /Hif2␣ F/F mice compared with littermate controls Apc F/F mice, but there was no significant change in YAP1 target genes in the CDXERT2 Cre Apc F/F /Hif2␣ F/F mice compared with CDXERT2 Cre Apc F/F mice ( Fig. 4A ). Moreover, the increase of p-YAP1 and T-YAP1 protein after Apc disruption was not altered in mice with a HIF-2␣ disruption ( Fig. 4B ). Immunofluorescence staining with Ki67 and H&E staining showed increased cell proliferation in CDXERT2 Cre Apc F/F mice, whereas HIF-2␣ knock-out did not alter the tissue proliferation ( Fig. 4, C and D) . These results indicate that HIF-2␣ is not essential for the increase of YAP1 and its target gene expression in sporadic CRC models.
HIF-2␣ potentiation of YAP1 activity is not via kinase signaling or protein-protein interaction
Src family kinases can promote proliferation of intestinal epithelial cells through activation of YAP1, which contributes to the proper regulation of intestinal epithelial cell turnover and intestinal homeostasis (32) . To assess if HIF-2␣ potentiates YAP1 through Src, YAP1 reporter assays were performed after treatment with the Src inhibitor, SU6656. Cyr61 promoter luciferase was significantly increased when the cells were transfected with both HIF-2␣ and YAP1, but this potentiation was not inhibited when treated with SU6656 ( Fig. 5A, left panel) . The Src activity inhibition with SU6656 was confirmed by Western blot analysis ( Fig. 5A, right panel) . The PI3K-AKT 
The cross-talk between HIF-2␣ and YAP1
pathway is essential for cell survival (33) . AKT also alters YAP1 activity (34) ; however, AKT (MK2206) inhibitor did not affect the potentiation of YAP1 activity by HIF-2␣ ( Fig. 5B, left panel) . The phosphorylated AKT (p-AKT) inhibition by MK2206 was confirmed using Western blot analysis ( Fig. 5B, right panel) .
Recently we showed a novel cross-talk of HIF-2␣ with MEK1-ERK1/2 signaling (35) . MAPK pathways increase YAP1 activity (36) . Inhibition of MEK1 using two different inhibitors (GSK1120212 or PD325901) significantly decreased ERK activity, as the phosphorylated ERK (p-ERK) was inhibited ( Fig. 5C , right panel). The inhibition of MEK1 using GSK1120212 significantly decreased the CYR61 promoter activity induced by YAP1, but neither inhibitor decreased the HIF-2␣-induced potentiation to levels observed with YAP1 transfection (Fig. 5C , left panel). To test if HIF-2␣ and YAP1 could directly interact, FLAG-tagged YAP1 (YAP1-FLAG) and HIF-2␣ plasmids were co-transfected into HCT116 cells. A pulldown of FLAG and Western blot analysis for HIF-2␣ did not demonstrate any interaction (Fig. 5D ). Similarly, cells were transfected with NTAP (N-terminal affinity purification)-tagged HIF-2␣ (HIF-2␣-NTAP) and YAP1-FLAG plasmids. A pulldown of NTAP and blotting for FLAG also indicated no interaction between HIF-2␣ and YAP1 (Fig. 5D ). These data indicated that there is no direct protein binding between HIF-2␣ and YAP1.
Prostaglandin E2 (PGE2) is not essential for HIF-2␣ potentiation of YAP1 activity in CRC
A recent study demonstrates that PGE2 and the synthase needed for PGE2 production, cyclooxygenase-2 (COX2), are essential in YAP1 expression and transcriptional activity in CRC (37) . The COX2-PGE2 pathway is critical in CRC progression and non-steroidal inflammatory drugs, which are potent and selective inhibitors of COX2, are effective chemopreventative agents in CRC (38, 39) . PGE2 production is highly elevated in CRC via a HIF-2␣-dependent activation of COX2 (7) . To assess if HIF-2␣ leads to potentiation of YAP1 via COX2-PGE2 signaling loop, a colon tumor model dependent on HIF-2␣ activation was assessed (6, 7) . Mice with an intestine-specific disruption of Von Hippel Lindau (VHL) tumor suppressor protein led to constitutive HIF activation and an increase in HIF1␣ and HIF2␣ target genes Slc11a2, DcytB, Vegf, PDK1, and Ankrd37 (Fig. 6A) (40) . These mice crossed to a sporadic intestinal tumor model Apc min/ϩ leads to a robust increase in colon tumors that is dependent on HIF-2␣ (but not HIF-1␣) (Vhl ⌬IE ;Apc min/ϩ ) (6) . Moreover, our previous study demonstrates that intestinal epithelial cell activation of HIF-1␣ does not increase carcinogenesis or progression of colon cancer (41) . Vhl ⌬IE ;Apc min/ϩ and littermate control mice (Vhl F/F ;Apc min/ϩ ) were treated with the COX2 inhibitor nimesulide. Tumor tissue from both Vhl F/F ;Apc min/ϩ and Vhl ⌬IE ;Apc min/ϩ mice had significant increases of Cyr61 and Ctgf gene expression compared with normal tissue (Fig. 6B ). Nimesulide treatment significantly suppressed YAP1 target gene expression in Vhl F/F ;Apc min/ϩ tumor tissue ( Fig. 6B ). HIF-2␣ stabilization led to a further increase in Cyr61 and Ctgf, consistent with our data showing that HIF-2␣ can potentiate YAP1 signaling. Nimesulide did not decrease the HIF-2␣ potentiation of YAP1 target genes in tumor tissues ( Fig.  6B ). This suggests that the cross-talk between HIF-2␣ and YAP1 was PGE2-independent.
YAP1 is important for HIF-2␣-mediated cancer cell growth
Currently the mechanism by which HIF-2␣ leads to YAP1 potentiation is not clear. However, to understand if YAP1 activation is essential in hypoxia or HIF-2␣-induced colon cancer 
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cell growth, proliferation assays were assessed. RKO, SW480, and KM12 cell lines were incubated in either normoxia (21% O 2 ) or hypoxia (1% O 2 ) conditions. All three cell lines demonstrated a significant increase in HIF-1␣ and HIF-2␣ protein expression in hypoxia (Fig. 7A ). YAP1 was shown to be essential in hypoxic growth, as using our previously validated YAP1 siRNAs (siYAP1) (31) (Fig. 7B) . To address the specific role of HIF-2␣ and YAP1 in hypoxic growth, HCT116 cells were assessed that expressed both HIF-1␣ and HIF-2␣ (Fig. 7A ). HCT116-overexpressing HIF-2␣ or siYAP1 knockdown did not lead to significant changes in growth in normoxia. Under hypoxic conditions (1% O 2 ), cell growth was significantly inhibited, whereas the growth was increased in cells that overexpressed HIF-2␣. Cells that overexpressed HIF-2␣ but had a knockdown of YAP1 demonstrated a decrease in cell growth under hypoxia (Fig. 7C) . Interestingly, knockdown of YAP1 not only reversed the growth-protective effect of HIF-2␣ under hypoxia but also led to a decrease in growth under hypoxia. This result demonstrates that YAP1 is essential for HIF-2␣ and hypoxia-mediated growth.
Discussion
Hypoxia is a hallmark of solid tumors. Hypoxia can activate the expression of numerous genes involved in cell metabolism, cell survival, cell proliferation, and cell apoptosis. In the intestine, activation of HIF-2␣ but not HIF-1␣ promotes the development of CRC (6) . However, how HIF-2␣ contributes to proliferation is still not clear. Here, we demonstrate that HIF-2␣ promotes CRC cell growth via regulating YAP1 activity. The hippo pathway can be activated by cell density or mechanical cues (42, 43) , which leads to phosphorylation and degradation of the YAP/TAZ transcription factors (11) . A decrease in Hippo signaling leads to YAP and TAZ nuclear localization and activation of gene expression that promotes cell proliferation and survival. The persistent activation of YAP1 leads to tissue overgrowth and tumor formation in a broad range of tissues (27) .
Several studies have shown that HIF-2␣ induces proliferation via an increase in c-Myc activity (8) , inflammation (6, 44) , or disrupted iron homeostasis (45) . However, it has been suggested that hypoxia hinders cell growth (46 -49) and increases . HIF-2␣ disruption was not essential for YAP1 activity in sporadic tumors. A, Cyr61, Ctgf, HIF-2␣, and Slc11a2 gene expression in Apc F/F (n ϭ 6), CDXERT2 Cre Apc F/F (n ϭ 8), and CDXERT2 Cre Apc F/F /Hif2␣ F/F (n ϭ 6) colons. B, p-YAP1, T-YAP1 protein levels from Apc F/F , CDXERT2 Cre Apc F/F , and CDXERT2 Cre Apc F/F /Hif2␣ F/F mice colon tissue, GAPDH was used as a loading control. C, representative images for Ki67 immunofluorescent staining and H&E staining in APC F/F ; CDXERT2 Cre Apc F/F , and CDXERT2 Cre ;Apc F/F /Hif2␣ F/F colon tissue. D, quantification of Ki67 staining. *, p Ͻ 0.05; **, p Ͻ 0.01 compared to the Apc F/F group; #, p Ͻ 0.05 compared with the CDXERT2 Cre Apc F/F group. n.s., not significant.
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apoptosis (49, 50) , which is consistent with the decreased cell proliferation in our RKO, SW480, KM12, and HCT116 cells under hypoxia conditions. Here, we showed that HIF-2␣ is an activator for YAP1, which increases colon cancer cell growth. Our data showed that stabilized HIF-2␣ significantly increased YAP1 protein levels and downstream target gene Cyr61, Ctgf, and Tgfbr2 expression in Hif2␣ LSL/LSL;VillinCre mice as well as in the HIF-2␣-overexpressing HCT116 human colon cancer cell line. Indeed, HIF-2␣-induced cancer cell growth was inhibited when YAP1 was knocked down in various colon cancer cell lines, indicating that HIF-2␣-YAP1 cross-talk is important for tumorigenesis. Future work will focus on how the different 
HIF-2␣-induced growth proliferative mechanisms integrate and are regulated to increase CRC progression.
The mechanism by which HIF-2␣ induced YAP1 expression and activity was not through direct protein binding or promoter activation of YAP1 target genes but via indirect mechanism. The possible mechanisms that led to potentiation are not clear but are a major future focus. In our sporadic colon cancer mouse model, we demonstrated that the activation of YAP1 is HIF-2␣-independent. This is possibly due to other parallel pathways such as increased ␤-catenin resulting from tumor suppressor APC mutation. The dysregulation of YAP phosphorylation and nuclear localization has been extensively studied (51) (52) (53) . However, recent data have revealed that cancer samples have increased total YAP abundance (23, 54) . Our data support this recently proposed idea and provide a clinically relevant mechanism by which YAP activation by HIF-2␣ is increased in human colon cancers.
Previous studies have demonstrated that the activation of YAP1 leads to hyper-proliferation and spontaneous tumor formation in certain tissues, including the intestine (23, 55) . Recently, YAP-TEAD complex suppressor Verteporfin has shown potential as a anticancer treatment (31, 56) . However, YAP1 is a critical component of the ␤-catenin degradation complex, and disruption of YAP1 leads to an enhanced ␤-catenin activation and increased proliferation in the intestine (17) . Therefore, better therapeutic methods are necessary. Hypoxia can regulate YAP1 activity in hepatocellular cancerderived cell lines independent of HIF-1␣; however, HIF-2␣ was not assessed (57) . Moreover, a complimentary pathway was recently shown in which HIF-1␣ induces the Hippo coactivator TAZ and can serve as transcriptional co-activator (58) . Here, we demonstrate a novel mechanism of YAP1 regulation by HIF-2␣, which can serve as a potential therapeutic target for YAP1associated tumorigenesis.
In summary, we discovered that there is novel cross-talk between HIF-2␣ and YAP1, which is one of the mechanisms that HIF-2␣ can increase tumor genesis. Future studies focusing on YAP1 deletion in HIF-2␣-induced cancer models are needed to further understand this cross-talk.
Experimental procedures
Animals and treatments
Intestine-specific HIF-2␣-overexpressing mice (Hif2␣ LSL/LSL;VillinCre ) and sporadic colon tumor mouse models including CDXERT2 Cre /Apc F/F , CDXERT2 Cre Apc F/F /HIF2␣ F/F , Vhl ⌬IE ;Apc min/ϩ , and Vhl F/F Apc min/ϩ were maintained in standard cages in a light-and temperature-controlled room and 
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were fed with standard chow and water ad libitum. For the PGE2/COX2 inhibition study, normal tissue and tumor tissue samples were obtained from Vhl ⌬IE /Apc min/ϩ and Vhl F/F / Apc min/ϩ mice fed with powdered laboratory rodent diet 5001 (PMI Nutrition International LLC, Brentwood, MO) with or without 400 mg/kg nimesulide (Sigma) for 8 weeks. All the ani- 
mal studies were carried out in accordance with the Institute of Laboratory Animal Resources guidelines and approved by the University Committee on the Use and Care of Animals at the University of Michigan.
Cell culture and proliferation assays
All cells were maintained in complete DMEM medium (supplemented with 10% fetal bovine serum and 1% antibiotic/antimycotic agent) at 37°C in 5% CO 2 and 21% O 2 . For hypoxia experiments, cells were incubated in a hypoxia chamber (5% CO 2 and 1% O 2 ) at 37°C. Growth assays were performed using 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) reagent as previously described (31) .
Luciferase assay
Colon cancer cell lines (HCT-116 cells, SW480, KM12, and RKO cells) and an embryonic kidney cell line HEK293T were used. Cells were seeded into a 24-well plate at a cell density of 5 ϫ 10 4 cells per well. Enolase promoter luciferase reporter constructs Cyr61 or GTIIC activity reporter luciferase construct pGL4.47 (luc2P/SIE/Hygro) was co-transfected with YAP-1, HIF-2␣-TM (HIF-2␣ triple mutant for protein stabilization), or empty vector (EV) into cells with polyethyleneimine (PEI; Polysciences Inc., Warrington, PA). Cells were treated with 100 nM Src family kinase inhibitor SU6656, AKT inhibitor MK2206, MAPK/ERK1/2 inhibitors GSK, or PD (PD325901) at 24 h after transfection. Cells were lysed in reporter lysis buffer (Promega, Madison, WI), and firefly luciferase activity was measured and normalized to ␤-galactosidase activity 48 h after transfection.
Western blot analysis
Western blot analysis was performed as previously described (59) . Blots were probed with antibodies against ERK (catalog #4695, Cell Signaling Technology, Danvers, MA), p-ERK (catalog #9101, Cell Signaling Technology), AKT (catalog #4691, Cell Signaling Technology), p-AKT (catalog #4060, Cell Signaling Technology), Src (catalog #2109, Cell Signaling Technology), p-Src (catalog #6943, Cell Signaling Technology), YAP1 (catalog #4770, Sigma), p-YAP1(catalog #13008, Cell Signaling Technology), HIF-2␣ (catalog #NB100 -122, Novus Biologicals, Littleton, CO), GAPDH (catalog #sc-25778, Santa Cruz Biotechnology, Santa Cruz, CA), FLAG (catalog #F1804, Sigma), or NTAP (catalog #sc-33000, Santa Cruz Biotechnology) followed by incubation with the appropriate horseradish peroxidase-conjugated secondary antibodies (Cell Signaling Technology). Immuno-reactive protein species were detected using chemiluminescence methods.
Immunofluorescence
Sections were stained as previously described (59, 60) . Primary antibodies against Ki67(1:100; catalog #VP-K454, Vector Laboratories Inc., Burlingame, CA) and YAP1 (1:100; catalog #14074, Cell Signaling Technology, Danvers, MA) were used. H&E staining was also done as previously described (59) . The immunofluorescence was quantified using ImageJ150 software (created by Wayne Rasband, National Institutes of Health).
Quantitative real-time RT-PCR
RNA extraction, reverse transcription, and qPCR were described previously (61) . The primers used in the study are listed in Table 1 . Quantification cycle (Cq) values were normalized to ␤-actin and expressed as -fold difference from controls.
Statistical analysis
Results are expressed as the mean Ϯ S.D. Significance between two groups was calculated by an independent t test, and significance among different groups were tested using one-way analysis of variance followed by Dunnett's post-hoc comparisons.
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